Masato Ishigami

5.3k citations

70 papers · 4.2k indexed · 1 hit paper · h-index 33

Surgery top 2%
Epidemiology top 2%
Endocrinology, Diabetes and Metabolism top 1%
Molecular Biology top 10%
Cardiology and Cardiovascular Medicine top 2%

Co-authors: Shizuya Yamashita Yūji Matsuzawa Naohiko Sakai Ken‐ichi Hirano Makoto Nishida Shinji Kihara Akifumi Matsuyama Tohru Funahashi
Topics: Lipoproteins and Cardiovascular Health (30 papers)Diabetes, Cardiovascular Risks, and Lipoproteins (26 papers)Peroxisome Proliferator-Activated Receptors (17 papers)
Cited by: Endocrinology, Diabetes and Metabolism Cardiology and Cardiovascular Medicine Epidemiology
Journals: Journal of Biological Chemistry Circulation Journal of Clinical Investigation
Partner nations: Japan United States Germany

In The Last Decade

Masato Ishigami

68 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages

2001 1.1k citations Shinji Kihara, Makoto Nishida et al. profile →

Peers

Countries citing papers authored by Masato Ishigami

Since Specialization

Citations

This map shows the geographic impact of Masato Ishigami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masato Ishigami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masato Ishigami more than expected).

Fields of papers citing papers by Masato Ishigami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masato Ishigami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masato Ishigami. The network helps show where Masato Ishigami may publish in the future.

Co-authorship network of co-authors of Masato Ishigami

This figure shows the co-authorship network connecting the top 25 collaborators of Masato Ishigami. A scholar is included among the top collaborators of Masato Ishigami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masato Ishigami. Masato Ishigami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer 2023 ·Cancer Medicine ·Kōichi Goto,Yoshimasa Shiraishi,Haruyasu Murakami,Hidehito Horinouchi,Ryo Toyozawa,Masayuki Takeda,Makiko Uno,Nigel W. Crawford,(unknown),Takeshi Jimbo,Masato Ishigami,Gensuke Takayama,Shintaro Nakayama,Shoichi Ohwada,Makoto Nishio	6
2	Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study 2022 ·International Journal of Colorectal Disease ·Hisateru Yasui,Atsushi Takeno,Hiroki Hara,Hiroshi Imamura,Hiroki Akamatsu,Kazumasa Fujitani,Minoru Nakane,Chihiro Kondoh,Seigo Yukisawa,Junichiro Nasu,Yoshinori Miyata,Akitaka Makiyama,Hiroyasu Ishida,(unknown),(unknown),Masato Ishigami,Masahiro Sugihara,Atsushi Ochiai,Toshihiko Doi	8
3	570P A first-in-human phase I study of the AXL inhibitor DS-1205c in combination with gefitinib in subjects with EGFR-mutant NSCLC 2020 ·Annals of Oncology ·Makoto Nishio,Isamu Okamoto,Haruyasu Murakami,Hidehito Horinouchi,Ryo Toyozawa,Masayuki Takeda,Masatake Uno,(unknown),Takahiro Jimbo,Masato Ishigami,Gensuke Takayama,(unknown),(unknown),Eric D. Slosberg,Kōichi Goto	8
4	Temporary sequestration of cholesterol and phosphatidylcholine within extracellular domains of ABCA1 during nascent HDL generation 2018 ·Scientific Reports ·Masato Ishigami,(unknown),Kohjiro Nagao,(unknown),Yasuhisa Kimura,Noriyuki Kioka,Kazumitsu Ueda	37
5	ATPase activity of nucleotide binding domains of human MDR3 in the context of MDR1 2013 ·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ·Masato Ishigami,(unknown),Kohjiro Nagao,Yasuhisa Kimura,Michinori Matsuo,Noriyuki Kioka,Kazumitsu Ueda	15
6	Correlation of fasting serum apolipoprotein B‐48 with coronary artery disease prevalence 2012 ·European Journal of Clinical Investigation ·Daisaku Masuda,(unknown),Kenichi Tsujii,Miwako Inagaki,Kazuhiro Nakatani,Miyako Yuasa‐Kawase,Kazumi Tsubakio‐Yamamoto,Tohru Ohama,Makoto Nishida,Masato Ishigami,Toshiharu Kawamoto,Akifumi Matsuyama,Naohiko Sakai,Issei Komuro,Shizuya Yamashita	48
7	Fasting Serum Apolipoprotein B-48 Can be a Marker of Postprandial Hyperlipidemia 2011 ·Journal of Atherosclerosis and Thrombosis ·Daisaku Masuda,Naohiko Sakai,(unknown),(unknown),(unknown),Ryota Kawase,Hajime Nakaoka,Miwako Inagaki,Kazuhiro Nakatani,Miyako Yuasa‐Kawase,Kazumi Tsubakio‐Yamamoto,Tohru Ohama,Yumiko Nakagawa-Toyama,Makoto Nishida,Masato Ishigami,(unknown),Akifumi Matsuyama,Issei Komuro,Shizuya Yamashita	40
8	Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels 2011 ·Atherosclerosis ·Kazuhiro Nakatani,(unknown),Daisaku Masuda,(unknown),Tomoko Oya,Yasumasa Monden,(unknown),Ryota Kawase,Hajime Nakaoka,Miwako Inagaki,Miyako Yuasa‐Kawase,Kazumi Tsubakio‐Yamamoto,Tohru Ohama,Makoto Nishida,Masato Ishigami,Issei Komuro,Shizuya Yamashita	31
9	Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia 2009 ·European Journal of Clinical Investigation ·Daisaku Masuda,Yumiko Nakagawa-Toyama,Kazuhiro Nakatani,Masanao Inagaki,Kazumi Tsubakio‐Yamamoto,José C. Sandoval,(unknown),M. Nishida,Masato Ishigami,Shizuya Yamashita	76
10	Chylomicron remnants are increased in the postprandial state in CD36 deficiency 2008 ·Journal of Lipid Research ·Daisaku Masuda,Ken‐ichi Hirano,Hiroyuki Oku,José C. Sandoval,Ryota Kawase,Miyako Yuasa‐Kawase,(unknown),Masanori Takada,Kazumi Tsubakio‐Yamamoto,Yoshihiro Tochino,Masahiro Koseki,Fumihiko Matsuura,Makoto Nishida,Toshiharu Kawamoto,Masato Ishigami,Masatsugu Hori,Iichiro Shimomura,Shizuya Yamashita	87
11	Evaluation of a Homogeneous Assay for Measuring LDL-cholesterol in Hyperlipidemic Serum Specimens 2008 ·Journal of Atherosclerosis and Thrombosis ·Shizuya Yamashita,Mitsuhiro Nakamura,(unknown),Hiroyuki Oku,José C. Sandoval,Kazumi Tsubakio‐Yamamoto,(unknown),Daisaku Masuda,Masahiro Koseki,Fumihiko Matsuura,Iichiro Shimomura,Makoto Nishida,Masato Ishigami	12
12	Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages 2008 ·Biochemical and Biophysical Research Communications ·Kazumi Tsubakio‐Yamamoto,Fumihiko Matsuura,Masahiro Koseki,Hiroyuki Oku,José C. Sandoval,Miwako Inagaki,Kazuhiro Nakatani,Hajime Nakaoka,Ryota Kawase,Miyako Yuasa‐Kawase,Daisaku Masuda,Tohru Ohama,Norikazu Maeda,Yumiko Nakagawa-Toyama,Masato Ishigami,Makoto Nishida,Shinji Kihara,Iichiro Shimomura,Shizuya Yamashita	109
13	Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver 2007 ·Biochemical and Biophysical Research Communications ·Fumihiko Matsuura,Hiroyuki Oku,Masahiro Koseki,José C. Sandoval,Miyako Yuasa‐Kawase,Kazumi Tsubakio‐Yamamoto,Daisaku Masuda,Norikazu Maeda,Kenichi Tsujii,Masato Ishigami,Makoto Nishida,Ken‐ichi Hirano,Shinji Kihara,Masatsugu Hori,Iichiro Shimomura,Shizuya Yamashita	126
14	Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients 2006 ·Molecular and Cellular Biochemistry ·Shizuya Yamashita,Ken‐ichi Hirano,Takahiro Kuwasako,Mohamed Janabi,(unknown),Masato Ishigami,Naohiko Sakai	115
15	Measurement of Cholesterol Efflux from Monocyte-Derived Macrophages of Patients with Llpid Disorders and Atherosclerotic Cardiovascular Diseases 2003 ·Japanese Circulation Journal-english Edition ·Kenichi Tsujii,Ken‐ichi Hirano,Zhongyan Zhang,Fumihiko Matsuura,Tohru Ohama,Takahiro Kuwasako,Masahiro Koseki,Akifumi Matsuyama,Kosuke Tsukamoto,(unknown),(unknown),Masato Ishigami,Naohiko Sakai,Hisatoyo Hiraoka,Tadashi Nakamura,Shizuya Yamashita,Yūji Matsuzawa	1
16	Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats 2002 ·Journal of Hepatology ·(unknown),Shizuya Yamashita,Masato Ishigami,Naohiko Sakai,Ken‐ichi Hirano,Minoru Tahara,Kunio Matsumoto,Toshikazu Nakamura,Yūji Matsuzawa	71
17	Dominant expression of ATP-binding cassette transporter-1 on basolateral surface of Caco-2 cells stimulated by LXR/RXR ligands 2002 ·Biochemical and Biophysical Research Communications ·Tohru Ohama,Ken‐ichi Hirano,Zhongyan Zhang,Ryo Aoki,Kenichi Tsujii,Yumiko Nakagawa-Toyama,Kosuke Tsukamoto,Chiaki Ikegami,Akifumi Matsuyama,Masato Ishigami,Naohiko Sakai,Hisatoyo Hiraoka,Kazumitsu Ueda,Shizuya Yamashita,Yūji Matsuzawa	60
18	Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypocholesterolemia—a possible pathogenesis of necrobiotic xanthogranuloma 1999 ·Atherosclerosis ·Fumihiko Matsuura,Shizuya Yamashita,Ken‐ichi Hirano,Masato Ishigami,Hisatoyo Hiraoka,Ritsu Tamura,Tsutomu Nakagawa,Makoto Nishida,Naohiko Sakai,Tadashi Nakamura,Shuichi Nozaki,Tohru Funahashi,Chiho Matsumoto,Mari Higashiyama,(unknown),Yuji Matsuzawa	48
19	Molecular Disorders of Cholesteryl Ester Transfer Protein 1996 ·Journal of Atherosclerosis and Thrombosis ·Shizuya Yamashita,Takeshi Arai,Ken‐ichi Hirano,Naohiko Sakai,Masato Ishigami,Norimichi Nakajima,Yūji Matsuzawa	6
20	Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. 1995 ·Journal of Clinical Investigation ·Satoshi Nozaki,Hirokazu Kashiwagi,Shizuya Yamashita,Tsutomu Nakagawa,(unknown),Yoshiaki Tomiyama,Atsuyuki Nakata,Masato Ishigami,Jun-ichiro Miyagawa,Kaoru Kameda-Takemura	273

About Masato Ishigami

Masato Ishigami is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cancer Research, having authored 70 papers that have together received 4.2k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (30 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (26 papers) and Peroxisome Proliferator-Activated Receptors (17 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.2k citations), Cardiology and Cardiovascular Medicine (1.0k citations) and Epidemiology (1.5k citations). Masato Ishigami has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Shizuya Yamashita, Yūji Matsuzawa, Naohiko Sakai, Ken‐ichi Hirano, Makoto Nishida, Shinji Kihara, Akifumi Matsuyama, Tohru Funahashi, Kaoru Kameda-Takemura and Hiroshi Kuriyama. Their work appears in journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact